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Fragile X-associated tremor/ataxia syndrome
(FXTAS) is a recently described neurodegener-
ative disorder of older adult carriers of premuta-
tion alleles (60–200 CGG repeats) in the fragile X
mental retardation gene (FMR1). It has been
proposed that FXTAS is an RNA-mediated neu-
rodegenerative disease caused by the titration
of RNA-binding proteins by the CGG repeats.
To test this hypothesis, we utilize a transgenic
Drosophila model of FXTAS that expresses
a premutation-length repeat (90 CGG repeats)
from the 50 UTR of the human FMR1 gene and
displays neuronal degeneration. Here, we
show that overexpression of RNA-binding pro-
teins hnRNP A2/B1 and CUGBP1 suppresses
the phenotype of the CGG transgenic fly. Fur-
thermore, we show that hnRNP A2/B1 directly
interacts with riboCGG repeats and that the
CUGBP1 protein interacts with the riboCGG
repeats via hnRNP A2/B1.
INTRODUCTION
Fragile X syndrome is the most common form of hereditary
mental retardation, occurring in individuals lacking the
fragile X mental retardation protein (FMRP). Large expan-
sions of the CGG trinucleotide repeat (>200 repeats) in the
50 untranslated region of the FMR1 gene leads to silencing
of its transcript and the loss of the FMR1 product, FMRP
(Warren and Sherman, 2001). Most individuals in the gen-
eral population carry fewer than 60 CGG repeats, while
those individuals with CGG repeat expansions between
60 and 200 are referred to as premutation carriers. These
alleles support transcription of FMR1, and hence premu-
tation carriers are phenotypically normal with respect to
the features of fragile X syndrome. However, fragile X-
associated tremor/ataxia syndrome (FXTAS), a neuro-degenerative disorder, has recently been described in
a subgroup of premutation adult carriers (Hagerman and
Hagerman, 2004). FXTAS is characterized by tremor,
gait problems, cerebellar dysfunction, cognitive decline,
and parkinsonism associated with generalized brain atro-
phy (Hagerman et al., 2001). Eosinophilic intranuclear in-
clusions in both neuronal and astroglial cells, Purkinje
cell drop out, and Purkinje axonal torpedos have been ob-
served in postmortem examinations of the brains of pre-
mutation carrier males (Greco et al., 2002). The lack of as-
sociation of features of fragile X syndrome with FXTAS
(and vice versa) suggests an improbable relationship be-
tween the FMR1 protein and FXTAS. A distinguishing
characteristic of premutation carriers is the production
of FMR1 transcripts with extended CGG repeats, while
patients with fragile X syndrome produce little or no
FMR1 mRNA. Additionally, increased FMR1 mRNA levels
have been observed in the premutation carriers and in a
‘‘knockin’’ CGG mouse model, supporting the idea that
FXTAS is an RNA-mediated neurodegenerative disorder
(Tassone et al., 2000; Willemsen et al., 2003). A transgenic
fly model expressing the 50 UTR of the human FMR1 gene
with 90 CGG repeats showed that the premutation-length
repeat out of the FMR1mRNA context could cause neuro-
degeneration (Jin et al., 2003). Flies expressing these
CGG repeats in the eye display disorganized ommatidia,
depigmentation, and progressive loss of photoreceptor
neurons. As shown by temperature-shift experiments,
these phenotypes are late onset and not a consequence
of developmental abnormalities (Jin et al., 2003). The eye
phenotype could be suppressed by overexpressing
hsp70, a chaperone involved in protein folding (Jin et al.,
2003). These results suggest that transcription of the
CGG90 repeats leads to an RNA-mediated neurodegen-
erative disease, possibly via influencing RNA-binding
proteins.
To test this model and to define modifiers of the rCGG-
repeat-mediated eye phenotype, we carried out a genetic
screen making use of a collection of candidate RNA-
binding proteins. CUGBP1, an RNA-binding protein dis-
covered for its ability to bind CUG repeats and implicatedNeuron 55, 565–571, August 16, 2007 ª2007 Elsevier Inc. 565
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CUGBP1 and hnRNPA2/B1 in RiboCGG Neurodegenerationin myotonic dystrophy type 1 (DM1) (Timchenko et al.,
1996, 2001, 2004), was identified in our screen as the
sole modifier among the candidates. We show that over-
expression of CUGBP1 is able to suppress the neuro-
degenerative eye phenotype of the CGG90 transgenic
flies. Furthermore, we show that the CUGBP1 protein is
able to interact with the CGG repeats via hnRNP A2/B1,
a riboCGG-binding protein. hnRNP A2/B1 is an RNA-
binding protein that is present in intranuclear inclusions
of FXTAS patients (Iwahashi et al., 2006). We demonstrate
that hnRNP A2/B1 binds directly to the CGG repeats (see
Jin et al., 2007 [this issue of Neuron]; and this paper) and
that overexpression of hnRNP A2/B1 and its two Droso-
phila homologs suppresses the rCGG-repeat-mediated
neurodegenerative eye phenotype.
RESULTS
Overexpression of CUGBP1 Suppresses
the rCGG-Induced Neurodegeneration
We carried out a genetic screen on the CGG90 neurode-
generative eye phenotype to identify potential RNA-
binding proteins that modify the rCGG-mediated toxicity.
The screen involved directing the expression of premuta-
tion-length CGG repeats to the eye with the Gmr-GAL4
driver using the Drosophila GAL4/UAS system. This was
followed by crossing Gmr-GAL4, UAS-(CGG)90-EGFP
transgenic flies with flies mutant in genes coding for 60
different candidate RNA-binding proteins that were either
created by our group or were available from the Blooming-
ton stock center (Table 1). The progeny were examined for
potential suppression or enhancement of the disorganized
eye phenotype by comparison to control rCGG flies (Table
1). Through this screen, we identified one modifier of
rCGG-mediated neurodegeneration, CUGBP1. Figure 1
shows that overexpression of human CUGBP1 sup-
presses the neurodegenerative phenotype of the CGG90
transgenic fly. Given the role of CUGBP1 in myotonic dys-
trophy type 1 (DM1), we also examined the other major
protein implicated in DM1, muscle blind-like protein 1
(MBNL1) (Kanadia et al., 2003; Ranum and Day, 2004).
We did not observe a genetic interaction between
MBNL1 and rCGG-mediated neurodegeneration (Table 1
and data not shown). This is unlikely to be due to inade-
quate levels of expression of MBNL1, since the same lines
have been shown to modify the eye toxicity and muscle
degeneration phenotypes in a fly model of myotonic
dystrophy (de Haro et al., 2006).
CUGBP1 Interacts with rCGG Repeats
via hnRNP A2/B1
Similar to the DM1 model, it has been proposed that the
lengthy rCGG repeats sequester RNA-binding proteins
from their normal function(s), which leads to neuronal de-
generation (Hagerman and Hagerman, 2002; Jin et al.,
2003). Therefore, to understand how CUGBP1 modulates
rCGG-mediated toxicity, we tested whether CUGBP1566 Neuron 55, 565–571, August 16, 2007 ª2007 Elsevier Inc.could bind rCGG repeats. We did not detect a direct inter-
action between CUGBP1 and rCGG repeats (data not
shown), which is consistent with a previous report (Tim-
chenko et al., 1996). Next, we reasoned that CUGBP1
might interact indirectly with rCGG repeats via rCGGBPs;
thus, we turned to interactions between CUGBP1 and
rCGGBPs. hnRNPA2/B1 and Pur a are the two RNA-
binding proteins identified to bind rCGG repeats in a paral-
lel biochemical screen (Jin et al., 2007). Therefore, we
tested the interactions between Pur a or hnRNP A2/B1
with CUGBP1. We found that endogenous Pur a did not
coimmunoprecipitate with CUGBP1 (data not shown).
However, endogenous hnRNP A2/B1 coimmunoprecipi-
tated with endogenous CUGBP1 from mouse brain ly-
sates, and this interaction is RNA independent (Figures
2A–2C), which suggests that a distinct complex is formed
between CUGBP1 and hnRNP A2/B1, independent of
Pur a. Also, we showed that CUGBP1 does not interact
with other RNA-binding proteins, hnRNP A3 and FMRP,
which suggests a specific interaction of CUGBP1 with
hnRNP A2/B1 (Figure 2A). To confirm that the interaction
between CUGBP1 and hnRNP A2/B1 is relevant to FXTAS
pathogenesis, we investigated whether a complex is
formed between all three components: CUGBP1, hnRNP
A2/B1, and the rCGG repeats. Using in vitro-translated
protein, we found that CUGBP1 bound to rCGG repeats
in the presence of hnRNP A2/B1 (Figure 2D). These obser-
vations suggest that the modulation of rCGG-mediated
eye phenotype by CUGBP1 is through hnRNP A2/B1. To
further investigate whether this physical interaction is rel-
evant in vivo, we tested for possible genetic interactions
between CUGBP1 and hnRNP A2/B1. We found that
coexpression of Drosophila homologs of hnRNP A2/B1
proteins suppresses the rough eye phenotype caused by
high expression of CUGBP1 (Figure 3). This suggests that
these proteins might antagonize each other’s biological
function/s, although this relationship may or may not be
relevant to FXTAS pathogenesis.
hnRNP A2/B1 Interacts with the rCGG Repeats
We confirmed the interaction between rCGG repeats and
hnRNP A2/B1 by performing gel-shift assays using the an-
tibody against hnRNP A2/B1 in mouse cerebellar lysates,
the brain region most affected in FXTAS (Greco et al.,
2006). The addition of antibody against hnRNP A2/B1
leads to a supershift, indicating that hnRNP A2/B1 is pres-
ent in the rCGG-protein complex (Figure 4A). We also car-
ried out binding reactions of both cytoplasmic and nuclear
mouse cerebellar lysates, with CGG105 as well as with
a normal length CGG30 biotinylated RNA. The captured
proteins were analyzed using antibody against hnRNP
A2/B1. We found that both normal (30 repeats) and pre-
mutation (105 repeats) length rCGG repeats could bind
to hnRNP A2/B1. However, this interaction is most evident
in the cytoplasmic mouse cerebellar lysates, despite the
finding that hnRNP A2/B1 is present in both the cytoplasm
and nuclei (Figure 4B). Nuclear hnRNPA2/B1 shows little
or no interaction with rCGG repeats, suggesting that
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CUGBP1 and hnRNPA2/B1 in RiboCGG NeurodegenerationTable 1. Candidate RNA-Binding Proteins Screened
to Identify Modifiers of the rCGG-Mediated
Neurodegenerative Eye Phenotype
Gene
Loss-of-Function
Allele
Overexpression
Allele
ALY Aly02267
ARET AretQBaretBG00614
aretBG01566
CUGBP uascugbpm2a*,
uascugbpm2e*
ATX2 atx206490 atx2EP3145
BICC bicC4
BICD bicDr5
BL blKG02524
BOL bol1, bolEP584
CPO cpo01432
DSX dsx18
EIF4A eif4ak01501 eif4aEP1011
EIF4E eif4e07238 eif4eEP3371
FNE P(uasfne.C)4-
10B2
FMR1 fmr1Delta113M P(uasfmr1.Z)3
HEPH heph03429
HOIP hoipk07104
HOW howEP858, howj5B5
HRB27C hrb27c02647
HRB87F Hrb87fKG02089
HRB98DE Hrb98 deEY01550,
hrb98 deZCL0558
IMP impEP760,
impEP1433
IRP-1B irp-1bEP961
LARK larkEP3259 P(uaslark-
3HA)23A
L(3)02094 L(3)02094
MSI msi1
MSL-3 msl-3EP3144,
msl-3KG00939
MUB mubEP3623
MUSCLEBLIND mbnP15144 uasmbnl1
(M10M)
MXC mxcG48
NOS nosL7, nosj3B6
PAPB pabpk10109
PAPB2 pabp2EP2264
PIWI piwi06843
PUM pumbem pumEP3461some modification(s) of the protein in either the nucleus or
cytoplasm alters its ability to bind the rCGG repeats.
To test whether hnRNP A2/B1 directly interacts with
rCGG repeats, we isolated the full-length cDNA encoding
human hnRNP A2/B1 (A2 form) for in vitro translation. This
protein was incubated with identical molar quantities of
biotinylated normal (30 repeats) or premutation (105 re-
peats) length rCGG repeats. We demonstrated that
hnRNP A2/B1 directly interacts with the rCGG repeats
and that increased binding of the protein to the premuta-
tion-length rCGG repeats is observed (Figure 4C). Also,
we note that transgenic flies expressing normal length
rCGG repeats do not have a rough eye phenotype (see
Figure S1 in the Supplemental Data available with this
article online).
Table 1. Continued
Gene
Loss-of-Function
Allele
Overexpression
Allele
PUF68 puf68EP3058
QKR58E-2 qkr58e-2KG07766
QKR58E-3 qkr58e-3EP2493,
qkr58e-3EY02038
RBP97D rb97d1
RBP9 rbp9BG02784
RIN rinEP920
RM62 rm62EP 3607
RNPS1 rnpsEP1O82
SC35 sc35KG02986
SLBP slbpEP3182
SMG smg1
SnRNP70K snRNP70k02107
SPEN spenk06805
SQD sqdj6E3 sqdEP746
STAU Staury9, stau1
SXL sxlf1
TBPH tbphKG08578
TRA2 tra2KG08361
TSU tsuEP567
U2A u2a1
U2AF38 u2af3806751,
u2af38k14504
VIG vigEP812
YTR ytrk13108, ytrEP2136
ZN72D zn72DBG02677
Putative loss-of-function and overexpression alleles of a col-
lection of RNA-binding proteins. *CUGBP1 overexpression
was confirmed for this study by western blot analysis (data
not shown).Neuron 55, 565–571, August 16, 2007 ª2007 Elsevier Inc. 567
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CUGBP1 and hnRNPA2/B1 in RiboCGG NeurodegenerationOverexpression of Human and Two Drosophila
Homologs of hnRNP A2/B1 Suppresses
the rCGG-Mediated Phenotype
To further explore the functional significance of the asso-
ciation between hnRNP A2/B1 and rCGG repeats, we
generated transgenic lines expressing members of the
hnRNP A2/B1 family of proteins. Drosophila genes
Hrb87F and Hrb98DE encode the fly proteins HRB87F
and HRB98DE (also known as hrp36 and hrp38, respec-
tively) (Zu et al., 1996), which are the closest Drosophila
homologs for mammalian hnRNP A2/B1 protein (55%
identity). We generated UAS lines that overexpress human
hnRNP A2/B1, Hrb87F, or Hrb98DE in the presence of
a GAL4 driver and crossed those lines with transgenic flies
expressing 90 CGG repeat. We found that overexpression
of either human hnRNP A2/B1, Hrb87F, or Hrb98DE sup-
presses the rCGG-mediated eye toxicity (Figure 4D). This
result suggests that hnRNP A2/B1 is also involved in
rCGG-mediated neurodegeneration. Furthermore, it sup-
ports the model that titration of these proteins by the
rCGG repeats prevents them from carrying out their
functions, because overexpression of these proteins
suppresses the neurodegenerative phenotype of flies ex-
pressing rCGG repeats. Additionally, flies that are homo-
zygous null for Hrb87F present with a mild rough eye phe-
notype and loss of photoreceptor neurons (Sengupta and
Lakhotia, 2006), which is in agreement with the titration
model.
DISCUSSION
FXTAS is a neurodegenerative disorder recognized in
some fragile X syndrome premutation carriers with
FMR1 alleles containing 55–200 CGG repeats (Hagerman
and Hagerman, 2004). Previous studies have demon-
Figure 1. CUGBP1 Modulates the rCGG-Mediated Neuro-
degenerative Eye Phenotype
Overexpression of CUGBP1 suppresses rCGG-mediated eye toxicity.
From left to right: a fly expressing (CGG)90-EGFP (GMR-GAL4 UAS:
CGG90/UAS: EGFP) has disorganized, fused ommatidia; middle,
a fly expressing (CGG)90-EGFP and CUGBP1 (GMR-GAL4 UAS:
CGG90/+; UAS: CUGBP/+) has restored, organized ommatidia; a fly
expressing CUGBP1 (GMR-GAL4/+; UAS: CUGBP/+) has organized
ommatidia. The crosses were performed at 22C, and Gmr-GAL4
was used.568 Neuron 55, 565–571, August 16, 2007 ª2007 Elsevier Inc.strated that FXTAS is RNA mediated and caused by ex-
panded fragile X premutation rCGG repeats (Arocena
et al., 2005; Jin et al., 2003; Willemsen et al., 2003). Our
studies have tested the hypothesis that RNA-binding
proteins are involved in FXTAS pathogenesis, and we
report that CUGBP1 and hnRNPA2/B1 are two such RNA-
binding proteins.
Figure 2. CUGBP1 Interacts with rCGG Repeats through
hnRNP A2/B1
Immunoprecipitation (IP) was performed on mouse brain lysates using
anti-CUGBP1 (A) or anti-hnRNP A2/B1 (B) antibody with IgG as a neg-
ative control. The immunoprecipitates were analyzed by immunoblot-
ting with antibodies specific to hnRNP A2/B1, hnRNP A3, FMRP, or
CUGBP1. FMRP and hnRNP A3 westerns were performed using differ-
ent gels. Ten percent of the input used for IP was run in parallel. (C) Im-
munoprecipitation (IP) was performed on mouse brain lysates with
RNase using anti-CUGBP1 and analyzed by immunoblotting to hnRNP
A2/B1. (D) In vitro-translated proteins were incubated with biotinylated
rCGG repeats; western blot data shows that CUGBP1 interacts with
rCGG repeats in the presence of hnRNP A2/B1 (lanes 3 and 4).
Figure 3. Overexpression of Drosophila hnRNP A2/B1 Homo-
logs Suppress the CUGBP1 Rough Eye Phenotype
From left to right: a fly expressing CUGBP1 (GMR-GAL4/+; UAS:
CUGBP/+) has disorganized ommatidia; a fly expressing CUGBP1
and Hrb87F (GMR-GAL4/+; UAS: CUGBP/Hrb87F) or a fly expressing
CUGBP1 and Hrb98DE (GMR-GAL4/+; UAS: CUGBP/Hrb98DE) have
more well-organized ommatidia. The crosses were performed at 25C.
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CUGBP1 and hnRNPA2/B1 in RiboCGG NeurodegenerationFigure 4. Interaction between rCGG Re-
peats and hnRNP A2/B1 Modulates
rCGG-Mediated Neurodegeneration
(A) Gel supershift assay shows the binding of
hnRNP A2/B1 to the rCGG repeats. Lane 1,
100 bp RNA ladder; lane 2, rCGG probe only;
lanes 3, rCGG probe with mouse cerebellar
lysates; lanes 4–6, rCGG probe and mouse
cerebellar lysates with increasing amounts of
anti-hnRNP A2/B1 antibody.
(B) Mammalian hnRNP A2/B1 binds to rCGG
repeats. Western blot using an antibody
against hnRNP A2/B1 is shown. The biotiny-
lated rCGG repeats were incubated with mouse
cerebellar lysates and captured by Dynal
beads. FT represents flow through, while E indi-
cates the eluted proteins that bind to rCGG re-
peats. Both nuclear and cytoplasmic lysates
were used and indicated. 30 rCGG, 105 rCGG
repeats or beads alone were used in the binding
reactions. The last two lanes are nuclear protein
lysates and cytoplasmic lysates as inputs.
(C) hnRNP A2/B1 directly interacts with rCGG
repeats and shows increased binding to 105
rCGG repeats. An equal amount of in vitro-
translated hnRNP A2/B1 was incubated with
identical molar quantities of either biotinylated
30 rCGG repeats or 105 rCGG repeats; beads
alone as control. Input and bound fractions
are shown.
(D) Overexpression of hnRNP A2/B1 and its
Drosophila orthologs suppresses the rough
eye phenotype caused by the expression of
CGG repeats, and this suppression is main-
tained when coexpressed with CUGBP1
(Figure S2). From left to right: GMR-GAL4
UAS: CGG90/ UAS: EGFP, GMR-GAL4 UAS:
CGG90/+; UAS: Hrb98DE/+, GMR-GAL4
UAS: CGG90/+; UAS: Hrb87F/+, GMR-GAL4
UAS: CGG90/UAS: EGFP, GMR-GAL4 UAS:
CGG90/UAS: hnRNP A2/B1. Flies shown in
the first three panels are grown at 25C and
the last two panels at 22C.HnRNP A2/B1 and CUGBP1 in FXTAS
HnRNP A2/B1 was identified to bind rCGG repeats in
a parallel biochemical screen (Jin et al., 2007). We con-
firmed this interaction between rCGG repeats and hnRNP
A2/B1 in our studies. We found that both normal (30 re-
peats) and premutation (105 repeats) length rCGG repeats
could bind to hnRNP A2/B1. However, nuclear hnRNPA2/
B1 shows little or no interaction with rCGG repeats, sug-
gesting that some modification(s) of the protein in either
the nucleus or cytoplasm alters its ability to bind the
rCGG repeats. Indeed, the protein kinase casein kinase
2 is able to phosphorylate hnRNP A2/B1 in vivo (Pancetti
et al., 1999). The differential binding abilities of
hnRNPA2/B1 to rCGG repeats depending upon the pro-
tein’s cellular location suggest that cytoplasmic hnRNP
A2/B1 has an independent or distinct role from its function
in the nucleus. An alternative possibility to explain the dif-
ferential binding of hnRNP A2/B1 is that other proteins
compete with it for rCGG binding in the nuclear fraction.NIwahashi et al. (2006) identified more than 20 such proteins
in the nuclear inclusions of FXTAS patients.
Also, we found CUGBP1 has a modifier of the rCGG-
mediated eye phenotype through our candidate-based
genetic screen. We show that CUGBP1 is able to interact
with the rCGG repeats in the presence of hnRNP A2/B1.
Furthermore, we show that overexpression of either
CUGBP1 or hnRNPA2/B1 suppresses the eye phenotype
caused by the expression of fragile X premutation rCGG
repeats. These data support the model that titration of
these proteins by the rCGG repeats prevents them from
carrying out their functions, since overexpression of these
proteins suppresses the neurodegenerative phenotype of
flies expressing rCGG repeats.
The roles of hnRNP A2/B1 and CUGBP1 in the patho-
genesis of FXTAS are intriguing. In DM1, total CUGBP1
steady-state levels are increased, with increased nuclear
CUGBP1 and decreased CUGBP1 in the cytoplasm
(Ranum and Cooper, 2006). In our study, we found thateuron 55, 565–571, August 16, 2007 ª2007 Elsevier Inc. 569
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CUGBP1 and hnRNPA2/B1 in RiboCGG Neurodegenerationincreased levels of CUGBP1 suppress the neurodegener-
ative phenotype caused by the rCGG repeats. This is an
interesting and surprising observation, as increased levels
of CUGBP1 are implicated in DM1. However, the findings
that cytoplasmic hnRNP A2/B1 interacts strongly with
rCGG and that CUGBP1 is able to interact with rCGG re-
peats via hnRNP A2/B1 suggest that principally cytoplas-
mic functions are compromised. This is consistent with
the reduction of cytoplasmic CUGBP1 found in DM1.
MBNL1, the other major protein implicated in myotonic
dystrophy, was found in the nuclear inclusions of FXTAS
patients (Iwahashi et al., 2006). However, we did not de-
tect a modification on the rCGG repeat eye phenotype
by modulating MBNL1 levels. This result raises the issue
of the functional significance of a protein that is found in
inclusions. The observation of widespread nuclear ubiqui-
tin and hsp70-positive inclusions in affected tissues of
FXTAS (Greco et al., 2002) suggested that these play a di-
rect role in pathology, possibly by sequestering factors in
a manner similar to that proposed in DM1. The presence of
FMR1 mRNA in inclusions (Tassone et al., 2004) argues
that rCGG repeats may nucleate inclusions that contain
rCGGBPs. However, it is unlikely that the majority of
FMR1 mRNA is confined to inclusions, and the soluble
RNA may also interact aberrantly with RNA-binding pro-
teins. Thus, the presence of a protein in inclusions may
not be an indicator of a direct role in pathogenesis.
In summary, through both biochemical and genetic as-
says, we implicate the RNA-binding proteins CUGBP1,
hnRNP A2/B1, and Pur a (Pur a results are described in
Jin et al. [2007]) in the pathogenesis of FXTAS. Our data
support the model of FXTAS pathogenesis whereby these
RNA-binding proteins are titrated from their biological
functions. These results could also explain the incomplete
penetrance of FXTAS, as polymorphisms in expression
levels of these proteins could offer a protective effect to
a fraction of premutation carriers. More importantly, the
existing data suggest two distinct ways by which the
CGG repeat exerts its toxicity. In the nuclear inclusions,
rCGG repeats sequester RNA-binding proteins such as
hnRNP A2/B1 (observed in FXTAS patients). However,
our observations show that the interaction between
hnRNP A2/B1 and the rCGG repeats is most evident in
the cytoplasm. The data suggest another mechanism
whereby FMR1 mRNA that is not confined to the nucleus
may also interact aberrantly with RNA-binding proteins.
EXPERIMENTAL PROCEDURES
RNA-Binding Assays and Protein Identification
To prepare brain lysates, mouse brains were washed twice with phos-
phate-buffered saline (PBS) and homogenized in lysis buffer (10 mM
Tris-HCl [pH 7.6], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT). The sam-
ples were then centrifuged for 5 min at 10,000 rpm to pellet nuclei, and
the supernatant (cytoplasmic fraction) was collected and used for
RNA-binding assays. Radioactive-, biotin-, or fluorescent-labeled
CGG repeat RNAs were synthesized using the RNAMaxx High Yield
Transcription Kit (Stratagene). The RNA probe (100 ng) was incubated
with 20 mg brain lysates or with 50 ng in vitro-translated protein(s) at570 Neuron 55, 565–571, August 16, 2007 ª2007 Elsevier Inc.room temperature for 30 min in 13 binding buffer (20 mM Tris-HCl
[pH 7.6], 100 mM KCl, 5 mM MgCl2, 5 mM DTT, and 10% glycerol).
The binding reaction was loaded and separated on native polyacryl-
amide gel, which was analyzed via Storm 840 phosphorimager
(Amersham Biosciences Corp). For the binding reaction with biotiny-
lated RNAs, DynaBeads M-280 Streptavidin (Dynal, Invitrogen) were
used to capture the rCGG-protein complex. The beads were washed
before use and resuspended in binding buffer. The captured proteins
were subjected to western blots with anti-hnRNP A2/B1 (Santa Cruz
Biotechnology) and anti-CUGBP1 (Upstate) antibodies.
Immunoprecipitation
Mouse brains were collected and homogenized in 1 ml ice-cold lysis
buffer (10 mM Tris [pH 7.4], 150 mM NaCl, 30 mM EDTA, 0.5% Triton
X-100) with 23 complete protease inhibitors. All further manipulations
of the brain lysates were performed at 4C or on ice. Nuclei and debris
were pelleted at 10,000 3 g for 10 min; the supernatant was collected
and precleared for 1 hr with 100 ml recombinant protein G agarose (In-
vitrogen). Anti-CUGBP1 antibody (Upstate) or Anti-hnRNP A2/B1 anti-
body (Santa Cruz Biotechnology) was incubated with recombinant
protein G agarose at 4C for 2 hr and washed three times with lysis
buffer. The precleared lysates were immunoprecipitated with anti-
body-coated recombinant protein G agarose at 4C overnight. The
precipitated complexes were used for western blot. Anti-hnRNP A2/
B1 antibody (Santa Cruz Biotechnology), anti-hnRNP A3 (Santa Cruz
Biotechnology), anti-CUGBP1 (Upstate) antibody, or anti-FMRP (kind
gift from J.L. Mandel) was used for western blot. For RNase treatment,
the precleared lysate was incubated with RNase A (1 mg/ml) at 37C
for 15 min. Each sample was subjected to additional centrifugation
at 10,000 3 g before immunoprecipitation.
Drosophila Genetics
The pUAST constructs were generated by cloning full-length cDNAs,
including two lines each of Drosophila Hrb87F and Hrb98DE and hu-
man hnRNP A2/B1 into the pUAST transformation vectors. The con-
structs were confirmed by DNA sequencing and then injected in
a w1118 strain by standard methods. All the other UAS lines, insertions,
and GAL4 lines used in this study were obtained from the Bloomington
Drosophila stock center or generated in the lab. Fly lines were grown
on standard medium with yeast paste added. Genetic screen was
carried out at 22C; all other crosses were performed at 25C unless
indicated in the text.
Microscopy
For scanning electron microscopy (SEM) images, whole flies were
dehydrated in ethanol, dried with hexamethyldisilazane (Sigma), and
analyzed with an ISI DS-130 LaB6 SEM/STEM microscope.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/55/4/565/DC1/.
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